ArticleMediators of inflammation2026
Therapeutic Potential of Bee Venom and Capsicum annum Hydroethanolic Extract in Experimental Model of Rheumatoid Arthritis in Male Rats.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Potential of Bee Venom and Capsicum annum Hydroethanolic Extract in Experimental Model of Rheumatoid Arthritis in Male Rats.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRheumatoid arthritis (RA) is a long-term inflammatory disease linked to higher mortality, joint degeneration, and long-term disability. This study evaluated the anti-inflammatory, antioxidant, and immunomodulatory effects of Capsicum annuum (CAP) hydroethanolic extract and bee venom (BV) in Freund's complete adjuvant (FCA)-induced RA in rats.
methodsForty-eight rats were divided into six groups: normal control (NC), RA control, and RA groups orally treated with methotrexate (MTX) (0.25 mg/kg), CAP (100 mg/kg), BV (0.25 mg/kg), and CAP (100 mg/kg) + BV (0.25 mg/kg). RA was induced by intradermal injection of FCA (100 μL/rat) into a footpad of the right hind paw at two consecutive days, and treatments were administered for 3 weeks. The study assessed serum rheumatoid factor (RF), anticyclic citrullinated peptide (ACCP) antibodies (ACPAs), tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4), oxidative stress markers such as lipid peroxidation, and antioxidant parameters including superoxide dismutase (SOD) and reduced glutathione (GSH). Additionally, mRNA expression of various genes (inducible nitric oxide synthase [iNOS], endothelial nitric oxide synthase [eNOS], interleukin-1β [IL-1β], TNF-α, matrix metalloproteinase-1 [MMP-1], matrix metalloproteinase-3 [MMP-3], and glutathione reductase [GR]) were analyzed, alongside histopathological evaluation.
resultsThe data showed that CAP and/or BV significantly reduced serum inflammatory and oxidative stress biomarkers, enhanced the antioxidant defense system, and improved the histopathological changes of ankle joint. Gene expression analysis revealed downregulation of iNOS, eNOS, IL-1β, TNF-α, MMP-1, and MMP-3 gene expression, with upregulation of the GR gene expression. The combined CAP + BV treatment demonstrated the most potent antiarthritic effect.
conclusionCAP and BV exhibit promising potential for alleviating RA in rats, with their combined application showing the greatest efficacy. The antiarthritic effects may be mediated via suppression of oxidative stress and inflammation and enhancement of the antioxidant defense system in addition to the modulatory effects on MMP-1 and MMP-3 gene expression. Further clinical research is essential to evaluate their safety and effectiveness in human RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.